RxDoctor Payments Data

Onix Fuentes, APRN

Family · North Miami Beach, FLNPI 1477227973

Payments from drug & device makers

$652in general payments, 2019–2025

Across 25 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$121
  • Novartis$106
  • Amgen$78
  • Philips North America LLC$67
  • Ardelyx, Inc.$49
  • Aimmune Therapeutics, Inc.$47
  • plus $184 from 7 others

What the payments were for

  • Consulting fees$152%
  • Food & beverage$63798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$652 in reported general payments places this provider in the 60th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$4,973
Medicare patients
23
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$27,567
TrulicityDulaglutide15$21,746
Famotidine26$662
Memantine Hcl17$527
Atorvastatin Calcium43$521
Metoprolol Succinate34$362
Rosuvastatin Calcium50$269
Pravastatin Sodium21$213
Losartan Potassium14$189
Amlodipine Besylate43$162
Lisinopril17$144
Vitamin D2Ergocalciferol (Vitamin D2)13$137
Carvedilol14$136
Ezetimibe11$106
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide12$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$121$21,74615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 14,618 family providers in Florida.

Other family in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →